Clinical trials: Adult Acute Monoblastic Leukemia (M5a)
Leukemia
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them…
- Trial name
- NCT00006045
- Testing
- lintuzumab, cytarabine, etoposide
- Where
- 59 sites in United States, Belgium and 5 more
- Sponsor
- Facet Biotech
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a)
Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy
This partially randomized phase II trial studies the side effects and best way to give and best dose of cholecalciferol in treating patients with acute myeloid leukemia (AML) undergoing intensive induction chemotherapy.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2)
- Trial name
- NCT01521936
- Testing
- cholecalciferol, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia
Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia
This research trial studies multidrug resistance genes in patients with acute myeloid leukemia. Studying samples of bone marrow or blood from patients with cancer in the laboratory may help doctors learn more about changes that…
- Trial name
- NCT00898456
- Testing
- gene expression analysis, molecular genetic technique, polymorphism analysis
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as mitoxantrone, etoposide, and cytarabine, work in different ways to stop the…
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT01127009
- Testing
- bortezomib, mitoxantrone hydrochloride, etoposide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Case Comprehensive Cancer Center
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia
This phase I trial is studying the side effects and the best dose of entinostat when given together with sorafenib tosylate in treating patients with advanced or metastatic solid tumors or refractory or relapsed acute myeloid…
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT01159301
- Testing
- entinostat, sorafenib tosylate, pharmacological study
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Studying Tissue Samples to Learn More About Drug Resistance in Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about cancer and the development of drug resistance in patients.
- Trial name
- NCT00900380
- Testing
- flow cytometry, immunological diagnostic method, laboratory biomarker analysis
- Volunteers
- 40 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin and bortezomib in treating patients with relapsed or refractory hematologic cancer.
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT00103272
- Testing
- tanespimycin, bortezomib
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00089050
- Testing
- cyclosporine, gemtuzumab ozogamicin
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia
Biomarker Study of Chemotherapy Resistance and Outcomes in Samples From Older Patients With Acute Myeloid Leukemia
RATIONALE: Studying blood samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01421875
- Testing
- DNA methylation analysis, RNA analysis, gene expression analysis
- Volunteers
- 257 people
- Sponsor
- Eastern Cooperative Oncology Group
Leukemia
Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in cancer cells.
- Trial name
- NCT00156299
- Testing
- choline magnesium trisalicylate, Dexamethasone
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Rutgers, The State University of New Jersey
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase I trial studies the side effects and the best dose of lenalidomide when given together with combination chemotherapy in treating patients with relapsed or refractory acute myeloid leukemia.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT01904643
- Testing
- lenalidomide, mitoxantrone hydrochloride, etoposide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Stanford University
Leukemia
Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
RATIONALE: Giving chemotherapy before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT01020734
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- 2 sites in South Korea
- Volunteers
- 263 people
- Sponsor
- Asan Medical Center
Leukemia
Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy, such as cytarabine and clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00295841
- Testing
- clofarabine, cytarabine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Wake Forest University Health Sciences
Leukemia
Total-Body Irradiation Plus Stem Cell Transplantation And White Blood Cell Infusion in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by radiation therapy used to kill tumor cells.
- Trial name
- NCT00005801
- Testing
- therapeutic allogeneic lymphocytes, peripheral blood stem cell transplantation, radiation therapy
- Where
- 2 sites in United States
- Sponsor
- University of Colorado, Denver
Leukemia, Myelodysplastic Syndromes
Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Zosuquidar trihydrochloride, a modulator of multidrug resistance (MDR), may help daunorubicin and cytarabine…
- Trial name
- NCT00046930
- Testing
- filgrastim, sargramostim, cytarabine
- Where
- 92 sites in United States, Israel
- Volunteers
- 449 people
- Sponsor
- Eastern Cooperative Oncology Group
Leukemia, Myelodysplastic Syndromes
Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy, such as cytarabine and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00121303
- Testing
- cytarabine, daunorubicin hydrochloride, gemtuzumab ozogamicin
- Where
- 6 sites in United Kingdom
- Volunteers
- 600 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia
Drugs used in chemotherapy, such as flavopiridol, cytarabine, and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT00470197
- Testing
- alvocidib, cytarabine, mitoxantrone hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy
RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00739388
- Testing
- azacytidine
- Where
- 11 sites in Switzerland
- Volunteers
- 47 people
- Sponsor
- Swiss Cancer Institute
Leukemia
Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- AML-19 (NCT00091234)
- Testing
- gemtuzumab ozogamicin
- Where
- 45 sites in Belgium, Italy and 1 more
- Volunteers
- 279 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC